Finder is committed to editorial independence. While we receive compensation when you click links to partners, they do not influence our content.

How to buy Neuronetics (STIM) stock

Learn how to easily invest in Neuronetics stock.

Neuronetics, Inc
NASDAQ: STIM - USD
DIAGNOSTICS & RESEARCH
$13.50
-$0.04 (-0.30%)

Neuronetics, Inc is a diagnostics & research business based in the US. Neuronetics shares (STIM) are listed on the NASDAQ and all prices are listed in US Dollars. Neuronetics employs 147 staff and has a trailing 12-month revenue of around 0.00.

How to buy shares in Neuronetics

  1. Compare share trading platforms.Use our comparison table to help you find a platform that fits you.
  2. Open your brokerage account. Complete an application with your details.
  3. Confirm your payment details. Fund your account.
  4. Research the stock. Find the stock by name or ticker symbol – STIM – and research it before deciding if it's a good investment for you.
  5. Purchase now or later. Buy your desired number of shares with a market order or use a limit order to delay your purchase until the stock reaches a desired price.
  6. Check in on your investment. Optimize your portfolio by tracking your stock.

Neuronetics stock price (NASDAQ: STIM)

Use our graph to track the performance of STIM stocks over time.

Neuronetics shares at a glance

Information last updated 2021-07-23.
Latest market close$16.59
52-week range$2.61 - $22.43
50-day moving average $15.42
200-day moving average $14.53
Wall St. target price$21.50
PE ratio N/A
Dividend yield N/A (0%)
Earnings per share (TTM) $-1.44

Buy Neuronetics shares from these brokerages

Compare special offers, low fees and a wide range of types of investments among top trading platforms.
Name Product Stock trade fee Asset types Option trade fee Annual fee Signup bonus
Sofi Invest
$0
Stocks, ETFs, Cryptocurrency
N/A
0%
Get one free stock worth up to $1,000
Open an account
A free way to invest in stocks, ETFs and crypto.
Webull
$0
Stocks, Options, ETFs
$0
0%
Get one free stock valued between $3.00 and $300 when you open an account, one more with a deposit
Open an account
Margin financing rates start at 3.99%. No monthly subscription fees for margin.
Public
$0
Stocks, ETFs
N/A
$0 per month
Download and sign up with Public.com; approved accounts receive a free stock slice worth up to $70, selected from 9 popular stocks.
Open an account
Commission-free trading in stocks and ETFs with a social networking twist.
Robinhood
$0
Stocks, Options, ETFs
$0
0%
Free stock (chosen randomly with a value anywhere between $2.50 and $200)
Sign up using the "go to site" link
Make unlimited commission-free trades in stocks, funds, and options with Robinhood Financial.
Moomoo
$0 for US stocks
Stocks, Options, ETFs
$0
$0 per year
N/A
Trade stocks on the US, Hong Kong, Shanghai and Shenzhen markets.
loading

Compare up to 4 providers

*Signup bonus information updated weekly.

The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.

Is it a good time to buy Neuronetics stock?

The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.

This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.

Neuronetics price performance over time

Historical closes compared with the close of $16.59 from 2021-06-08

1 week (2021-07-14) N/A
1 month (2021-06-25) -3.32%
3 months (2021-04-21) N/A
6 months (2021-01-21) N/A
1 year (2020-07-21) N/A
2 years (2019-07-21) N/A
3 years (2018-07-21) N/A
5 years (2016-07-21) N/A

Neuronetics financials

Revenue TTM $50.1 million
Gross profit TTM $37.7 million
Return on assets TTM -8.85%
Return on equity TTM -32.81%
Profit margin -45.39%
Book value $3.96
Market capitalisation $348.8 million

TTM: trailing 12 months

Shorting Neuronetics shares

There are currently 1.9 million Neuronetics shares held short by investors – that's known as Neuronetics's "short interest". This figure is 28.2% up from 1.5 million last month.

There are a few different ways that this level of interest in shorting Neuronetics shares can be evaluated.

Neuronetics's "short interest ratio" (SIR)

Neuronetics's "short interest ratio" (SIR) is the quantity of Neuronetics shares currently shorted divided by the average quantity of Neuronetics shares traded daily (recently around 562140.17595308). Neuronetics's SIR currently stands at 3.41. In other words for every 100,000 Neuronetics shares traded daily on the market, roughly 3410 shares are currently held short.

However Neuronetics's short interest can also be evaluated against the total number of Neuronetics shares, or, against the total number of tradable Neuronetics shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case Neuronetics's short interest could be expressed as 0.07% of the outstanding shares (for every 100,000 Neuronetics shares in existence, roughly 70 shares are currently held short) or 0.0772% of the tradable shares (for every 100,000 tradable Neuronetics shares, roughly 77 shares are currently held short).

Such a low SIR usually points to an optimistic outlook for the share price, with fewer people currently willing to bet against Neuronetics.

Find out more about how you can short Neuronetics stock.

Neuronetics share dividends

We're not expecting Neuronetics to pay a dividend over the next 12 months.

Neuronetics share price volatility

Over the last 12 months, Neuronetics's shares have ranged in value from as little as $2.61 up to $22.43. A popular way to gauge a stock's volatility is its "beta".

Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Neuronetics's is 2.6637. This would suggest that Neuronetics's shares are significantly more volatile than the average for this exchange and represent a higher risk.

Neuronetics overview

Neuronetics, Inc. , a commercial stage medical technology company, designs, develops, and markets products for patients with psychiatric disorders in the United States and internationally. The company offers NeuroStar Advanced Therapy System, a non-invasive and non-systemic office-based treatment to treat adult patients with major depressive disorder. Its NeuroStar Advanced Therapy System uses transcranial magnetic stimulation to create a pulsed, MRI-strength magnetic field that induces electrical currents designed to stimulate specific areas of the brain associated with mood. The company sells its products through its sales and customer support team to psychiatrists. Neuronetics, Inc. was incorporated in 2003 and is headquartered in Malvern, Pennsylvania.

Neuronetics in the news

There are no recent company news

Frequently asked questions

What percentage of Neuronetics is owned by insiders or institutions?
Currently 7.039% of Neuronetics shares are held by insiders and 85.957% by institutions.
How many people work for Neuronetics?
Latest data suggests 147 work at Neuronetics.
When does the fiscal year end for Neuronetics?
Neuronetics's fiscal year ends in December.
Where is Neuronetics based?
Neuronetics's address is: 3222 Phoenixville Pike, Malvern, PA, United States, 19355
What is Neuronetics's ISIN number?
Neuronetics's international securities identification number is: US64131A1051
What is Neuronetics's CUSIP number?
Neuronetics's Committee on Uniform Securities Identification Procedures number is: 64131A105

More guides on Finder

Ask an Expert

You are about to post a question on finder.com:

  • Do not enter personal information (eg. surname, phone number, bank details) as your question will be made public
  • finder.com is a financial comparison and information service, not a bank or product provider
  • We cannot provide you with personal advice or recommendations
  • Your answer might already be waiting – check previous questions below to see if yours has already been asked

Finder.com provides guides and information on a range of products and services. Because our content is not financial advice, we suggest talking with a professional before you make any decision.

By submitting your comment or question, you agree to our Privacy and Cookies Policy and finder.com Terms of Use.

Questions and responses on finder.com are not provided, paid for or otherwise endorsed by any bank or brand. These banks and brands are not responsible for ensuring that comments are answered or accurate.
Go to site